Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608438 | 0.69 | SIGMAR1 (0.39) | SIGMAR1MC4RF2PLGELANE | |
| SCHEMBL5263685 | 0.67 | MAPT (0.40) | SIGMAR1MC4RLMNA | |
| SCHEMBL21348346 | 0.66 | GSK3A (0.44) | SIGMAR1F2PLGELANECTSG | |
| SCHEMBL1044027 | 0.61 | SIGMAR1 (0.52) | SIGMAR1MC4RF2PLGELANE | |
| SCHEMBL28953885 | 0.61 | GAA (0.44) | SIGMAR1MC4RELANECTSGTSHR | |
| Bromide SCHEMBL30533153 | 0.61 | SIGMAR1 (0.38) | SIGMAR1ADORA1MC4RF2PLG | |
| SCHEMBL25291649 | 0.60 | SIGMAR1 (0.37) | SIGMAR1MC4RF2PLGELANE | |
| SCHEMBL29809367 | 0.60 | MAPT (0.40) | SIGMAR1MC4RLMNA | |
| SCHEMBL5540890 | 0.60 | SIGMAR1 (0.46) | SIGMAR1MC4R | |
| SCHEMBL2228270 | 0.60 | SIGMAR1 (0.56) | SIGMAR1MC4RF2PLGELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | SIGMAR1 1943/4885ADORA1 4503/4885MC4R 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.